JP2006516572A
(en)
|
2003-01-14 |
2006-07-06 |
アリーナ ファーマシューティカルズ, インコーポレイテッド |
Prevention and treatment of 1,2,3-trisubstituted aryl derivatives and 1,2,3-trisubstituted heteroaryl derivatives as metabolic modulators and disorders associated with these derivatives such as diabetes and hyperglycemia
|
WO2004083388A2
(en)
|
2003-03-14 |
2004-09-30 |
Bristol-Myers Squibb Company |
Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
|
US20070032537A1
(en)
*
|
2003-06-13 |
2007-02-08 |
Arena Pharmaceuticals, Inc. |
5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases
|
MY157911A
(en)
|
2003-07-14 |
2016-08-15 |
Arena Pharm Inc |
Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
|
TWI258478B
(en)
|
2003-10-31 |
2006-07-21 |
Arena Pharm Inc |
Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
|
WO2005051937A2
(en)
|
2003-11-21 |
2005-06-09 |
Arena Pharmaceuticals, Inc. |
4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof
|
WO2006060461A1
(en)
|
2004-12-03 |
2006-06-08 |
Schering Corporation |
Substituted piperazines as cb1 antagonists
|
PE20060949A1
(en)
|
2004-12-23 |
2006-10-11 |
Arena Pharm Inc |
FUSED DERIVATIVES OF PIRAZOLE AS NIACIN RECEPTOR AGONISTS
|
MY148521A
(en)
|
2005-01-10 |
2013-04-30 |
Arena Pharm Inc |
Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
|
EP2778155A1
(en)
*
|
2007-01-31 |
2014-09-17 |
Vertex Pharmaceuticals Incorporated |
2-aminopyridine derivatives useful as kinase inhibitors
|
JP5702293B2
(en)
|
2008-11-10 |
2015-04-15 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
CN102300862B
(en)
|
2008-12-19 |
2016-11-23 |
沃泰克斯药物股份有限公司 |
Compound as ATR inhibitors of kinases
|
JP2013529200A
(en)
|
2010-05-12 |
2013-07-18 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Compounds useful as ATR kinase inhibitors
|
WO2011143419A1
(en)
|
2010-05-12 |
2011-11-17 |
Vertex Pharmaceuticals Incorporated |
Pyrazines useful as inhibitors of atr kinase
|
EP2568984A1
(en)
|
2010-05-12 |
2013-03-20 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
MX2012013082A
(en)
|
2010-05-12 |
2013-05-09 |
Vertex Pharma |
2 -aminopyridine derivatives useful as inhibitors of atr kinase.
|
WO2011143426A1
(en)
|
2010-05-12 |
2011-11-17 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
US9334244B2
(en)
|
2010-05-12 |
2016-05-10 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
MX2013000103A
(en)
|
2010-06-23 |
2013-06-13 |
Vertex Pharma |
Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase.
|
KR101871011B1
(en)
|
2010-09-22 |
2018-06-25 |
아레나 파마슈티칼스, 인크. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
MX2013011450A
(en)
|
2011-04-05 |
2014-02-03 |
Vertex Pharma |
Aminopyrazine compounds useful as inhibitors of tra kinase.
|
US9096602B2
(en)
|
2011-06-22 |
2015-08-04 |
Vertex Pharmaceuticals Incorporated |
Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors
|
JP2014520161A
(en)
|
2011-06-22 |
2014-08-21 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Compounds useful as ATR kinase inhibitors
|
WO2012178125A1
(en)
|
2011-06-22 |
2012-12-27 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
US8853217B2
(en)
|
2011-09-30 |
2014-10-07 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
WO2013049722A1
(en)
|
2011-09-30 |
2013-04-04 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
EP2940017B1
(en)
|
2011-09-30 |
2019-08-28 |
Vertex Pharmaceuticals Incorporated |
Process for making compounds useful as inhibitors of ATR kinase
|
EP2751088B1
(en)
|
2011-09-30 |
2016-04-13 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
EP2750679B1
(en)
|
2011-09-30 |
2021-09-01 |
Vertex Pharmaceuticals Incorporated |
Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors
|
WO2013071093A1
(en)
|
2011-11-09 |
2013-05-16 |
Vertex Pharmaceuticals Incorporated |
Pyrazine compounds useful as inhibitors of atr kinase
|
EP2776429A1
(en)
|
2011-11-09 |
2014-09-17 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
EP2776421A1
(en)
|
2011-11-09 |
2014-09-17 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
JP2015502925A
(en)
|
2011-11-09 |
2015-01-29 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Pyrazine compounds useful as inhibitors of ATR kinase
|
WO2013071090A1
(en)
|
2011-11-09 |
2013-05-16 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
HUE035253T2
(en)
|
2012-04-05 |
2018-05-02 |
Vertex Pharma |
Compounds useful as inhibitors of atr kinase and combination therapies thereof
|
CA2878625A1
(en)
|
2012-07-11 |
2014-01-16 |
Elcelyx Therapeutics, Inc. |
Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
|
EP2904406B1
(en)
|
2012-10-04 |
2018-03-21 |
Vertex Pharmaceuticals Incorporated |
Method for measuring atr inhibition mediated increases in dna damage
|
US8912198B2
(en)
|
2012-10-16 |
2014-12-16 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
HUE061909T2
(en)
|
2012-12-07 |
2023-08-28 |
Vertex Pharma |
Pyrazolo[1,5-a]pyrimidines useful as inhibitors of atr kinase for the treatment of cancer diseases
|
JP2016512815A
(en)
|
2013-03-15 |
2016-05-09 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Condensed pyrazolopyrimidine derivatives useful as inhibitors of ATR kinase
|
MX370390B
(en)
|
2013-12-06 |
2019-12-11 |
Vertex Pharma |
2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimid in-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof.
|
MX2016015874A
(en)
|
2014-06-05 |
2017-03-27 |
Vertex Pharma |
Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyrid in-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof.
|
SI3157566T1
(en)
|
2014-06-17 |
2019-08-30 |
Vertex Pharmaceuticals Incorporated |
Method for treating cancer using a combination of chk1 and atr inhibitors
|
KR20230151072A
(en)
|
2015-01-06 |
2023-10-31 |
아레나 파마슈티칼스, 인크. |
Methods of treating conditions related to the s1p1 receptor
|
WO2016209809A1
(en)
|
2015-06-22 |
2016-12-29 |
Arena Pharmaceuticals, Inc. |
Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(compound1) for use in sipi receptor-associated disorders
|
CA3000684A1
(en)
|
2015-09-30 |
2017-04-06 |
Vertex Pharmaceuticals Incorporated |
Method for treating cancer using a combination of dna damaging agents and atr inhibitors
|
WO2018151873A1
(en)
|
2017-02-16 |
2018-08-23 |
Arena Pharmaceuticals, Inc. |
Compounds and methods for treatment of primary biliary cholangitis
|